13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease

Kempiński, Radosław; Neubauer, Katarzyna; Wieczorek, Szymon; Dudkowiak, Robert; Jasińska, Maria; Poniewierka, Elżbieta

doi:10.17219/acem/60878

Cited by 10 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that there is a gradual decrease in the rate of metabolism and in the cumulative dose in steatosis and steatohepatitis [2,11,12]. Thus, in the presence of steatosis, it is observed the shift of the peak metabolism rate from 10 minutes to 20-30-40-50 minutes of the test [3,6].…”

Section: Discussionmentioning

confidence: 99%

“…However, indices of static biochemical markers allow only indirect conclusions to be drawn on the liver function in early stages of NAFLD [1,13]. Therefore, the use of breath tests to determine the metabolism of orally administered substrates, in particular methacetin, makes it possible to evaluate the functional status of the liver in dynamics in the normal condition and in NAFLD [1,12].…”

Section: Discussionmentioning

confidence: 99%

“…The second parameter for analysis of the metabolism kinetics of 13 C labeled methacetin is the time from the substrate intake to a peak of 13 CO 2 elimination in exhaled air. A shift in the peak of the metabolism rate from 10 to 50 minutes indicates the development of fatty liver infiltration [10,11,12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

13c-Methacetin Breathe Test in Early Diagnostics of Non-Alcoholic Fatty Liver Disease

Sklyarova

2021

Wiad Lek

View full text Add to dashboard Cite

The aim: Of the study was to evaluate the early utility changes of the 13C methacetin breath test parameters in patients with NAFLD. Materials and methods: There were included 50 subjects in the study, among them 35 patients had steatosis and 15 patients had steatohepatitis, including 35 (70.0%) male subjects and 15 (30.0%) female subjects. The control group included 17 apparently healthy volunteers, among them 10 (58.8%) subjects were male and 7 (41.2%) subjects were female. Results: It was determined that metabolism kinetics in case of liver steatosis was significant decreased more than 30% compared to the control group (p = 0.0001) and in case of steatohepatitis that decrease was more than 65% (p = 0.00001) compared with normal values. It resulted in less cumulative dose accumulation in steatosis (p = 0.00001) and steatohepatitis (p = 0.00001). Among the reasons for the decrease in the kinetics of metabolism in steatosis, there were insufficient response of hepatocytes on 10 minutes (<10 dose/h,%) in 40% of cases and reduction of metabolism rate amplitude at 20-40 minutes following methacetin administration. Conclusions: The results of 13C-methacetin breath test demonstrate that in patients with NAFLD there is a gradual slowing of metabolism rate in hepatocytes, which leads to a decrease in cumulative dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

13c-Methacetin Breathe Test in Early Diagnostics of Non-Alcoholic Fatty Liver Disease

Sklyarova

2021

Wiad Lek

View full text Add to dashboard Cite

show abstract

“…Although liver biopsy is still a gold standard to estimate fibrosis stage, new techniques are now under validation for noninvasive fibrosis evaluation, e.g. serum marker panels [10], elastography [11], and functional breath tests [12].…”

Section: Tgf-b1 Expression In Fatty Liver Diseasementioning

confidence: 99%

The immunoreactivity of TGF-b1 in non-alcoholic fatty liver disease

Kempiński¹,

Neubauer²,

Poniewierka³

et al. 2019

Folia Histochem Cytobiol.

Self Cite

View full text Add to dashboard Cite

Introduction. Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease which becomes a rapidly growing health problem in the Western countries. The development of the disease is most often connected to obesity. NAFLD is also considered as the hepatic manifestation of metabolic syndrome. Transforming growth factor b1 (TGF-b1) plays an important role in the pathogenesis of liver fibrosis, being involved in activation of hepatic stellate cells, stimulation of collagen gene transcription, and suppression of matrix metalloproteinase expression. The objective of the study was to evaluate by immunohistochemistry the expression of TGF-b1 in the liver tissue of NAFLD patients and correlate it with anthropometric, biochemical and routine histological parameters. Material and methods. The study group consisted of 48 patients with diagnosed NAFLD. Liver steatosis, NAFLD Activity Score (NAS) and METAVIR score of fibrosis were evaluated in liver biopsies. The immunoreactivity of TGF-b1 was evaluated semi-quantitatively separately in portal, septal, lobular hepatocytic and lobular sinusoidal liver compartments. The results were analyzed in regard to patients' clinical and biochemical parameters. Results. Neither steatosis nor NAS correlated with TGF-b1 expression in any liver compartment, whereas METAVIR score of fibrosis was associated with increased immunoreactivity of TGF-b1 in most of the studied liver compartments. TGF-b1 immunoreactivity showed positive correlation with patients' age and its expression in septal compartment disclosed positive correlation with body mass index, and waist and hip circumference. Hyaluronic acid serum level was positively and iron concentration was negatively associated with TGF-b1 expression in the selected consecutive liver compartments. Conclusions. The immunohistochemical expression of TGF-b1 may be complementary to routine methods of liver fibrosis evaluation.

show abstract

“…Although latest studies have not described sufficient sensitivity of each of the MBT parameters in detecting fibrosis in patients with NAFLD, a high negative predictive value of the test for discriminating patients with NAFLD and fibrosis stage F1 or higher was confirmed. The authors suggest therefore that MBT should be included in the diagnostic algorithm of NAFLD as a tool allowing us to identify patients without fibrosis, who do not require liver biopsy [ 26 ]. MBT is also considered to enable the assessment of liver function in patients waiting for a liver transplant as well as monitoring the organ's function after the patient received the graft [ 27 ].…”

Section: Application Of Mbt In Clinical Practicementioning

confidence: 99%

¹³C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application

Górowska-Kowolik

Chobot

Kwiecień

2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Assessment of the liver function, and the need of constant monitoring of the organ's capacity, concerns not only patients with primary liver diseases, but also those at risk of hepatopathies secondary to other chronic diseases. Most commonly, the diagnostics is based on measurements of static biochemical parameters, which allow us to draw conclusions only indirectly about the function and the degree of damage of the organ. On the other hand, liver biopsy is an invasive procedure and therefore it is associated with a considerable risk of complications. Dynamic tests enable us to assess quantitatively the organ's functional reserve by analyzing the kinetics of the metabolization of the substrate by the liver. In practice applied are breath tests using substances such as aminopyrine, caffeine, methacetin, erythromycin (for assessment of the microsomal function); phenylalanine, galactose (for assessment of the cytosolic function); methionine, octanoate, ketoisocaproic acid (for assessment of the mitochondrial function). The test with 13C methacetin belongs to the best described and most widely applied methods in noninvasive liver function assessment. Due to the rising availability of this method, knowledge concerning its limitations and controversies regarding the methodology, as well as its usefulness in chosen groups of patients, seems to be vital.

show abstract

13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease

Abstract: The (13)C-methacetin breath test could be a promising noninvasive tool for excluding at least F1 fibrosis in NAFLD patients.

Cited by 10 publications

References 5 publications

13c-Methacetin Breathe Test in Early Diagnostics of Non-Alcoholic Fatty Liver Disease

13c-Methacetin Breathe Test in Early Diagnostics of Non-Alcoholic Fatty Liver Disease

The immunoreactivity of TGF-b1 in non-alcoholic fatty liver disease

¹³C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application

Contact Info

Product

Resources

About

13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease

Abstract: The (13)C-methacetin breath test could be a promising noninvasive tool for excluding at least F1 fibrosis in NAFLD patients.

Cited by 10 publications

References 5 publications

13c-Methacetin Breathe Test in Early Diagnostics of Non-Alcoholic Fatty Liver Disease

13c-Methacetin Breathe Test in Early Diagnostics of Non-Alcoholic Fatty Liver Disease

The immunoreactivity of TGF-b1 in non-alcoholic fatty liver disease

13C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application

Contact Info

Product

Resources

About

¹³C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application